Nasal vaccine against Helicobacter pylori under development.
Nasal vaccine against Helicobacter pylori under development. Eurocine Vaccines has signed an agreement with research company HeliCure to develop a nasal vaccine against H pylori, a bacterium that causes gastric ulcers and gastric cancer. The project is in the pre-clinical development phase and is planned for tests in humans within two to three years. In addition to gastric ulcers, every year approximately 1 million people develop gastric cancer. The strong connection with H pylori means that a vaccine, which prevents infection with the bacterium, will also reduce the risk of gastric cancer.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||New vaccines|
|Publication:||Medical Laboratory Observer|
|Article Type:||Brief article|
|Date:||Dec 1, 2009|
|Previous Article:||CD4 level predicts cancer risk in HIV patients.|
|Next Article:||In memoriam.|